Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of NVA237 in Moderate to Severe COPD
NCT00510510Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2007
- Primary completion
- Jan 2008
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Aug 2007; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00510510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00510510.